... and moderate hemophilia and von Willebrand disease. Desmopressin also shortens the prolonged skin bleeding time in patients suffering from von Willebrand disease and is given to prevent or stop excessive bleeding in such conditions. 28 4 2009 © 1992 S. Karger AG, Basel 1992 Copyright / Drug...

...M. Magallón Martinez; F. Ortega; J. Pinilla 435 hemophiliacs are usually being attended in the La Paz hemophilia Center (Madrid, Spain). 257 (59%) of these patients have been infected by the human immunodeficiency virus (HIV-1) because of human plasma derivate substitution therapy. The infection...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Hemophilia HIV-1 infection FVIII...

...J. Martin-Villar In 1967, once urgent blood requirements had been resolved in La Paz Hospital, Madrid, Spain, and adequate supplies of plasma for cryoprecipitation, therefore, being available, a Hemophilia Unit (later Hemophilia Center) was set up to attend to the comprehensive care of hemophilia...

... steady-state concentrations of factor VIII in females heterozygous for hemophilia, the decreased steady-state concentrations of factor VIII in patients with type 1 (heterozygous) and type 3 (homozygous) von Willebrand disease, and the variable half-life of factor VIII in factor replacement therapy...

...M. de Tezanos Pinto; J. Fernandez; P.R. Perez Bianco Between 1960 and 1991, 156 episodes of central nervous system (CNS) bleeding were documented in 106 patients from a total population of 1,410 hemophiliacs (7.5%). Ninety-one hemophilia A patients presented 131 bleeding episodes; 15 hemophilia B...

...U. Hedner; S. Bjoern; S.S. Bernvil; L. Tengborn; L. Stigendahl FVIIa purified from human plasma and spontaneously activated during the purification procedure was given to 4 patients with hemophilia A and inhibitors against FVIIl:C in association with joint bleeds. A dose of 9–20 μg/kg b.w. (700...

...A. Gringeri; E. Santagostino; P.M. Mannucci Recombinant activated factor VII (rFVIIa) was used before and after inguinal hernioplasty to prevent bleeding in a patient with hemophilia A complicated by a high-potency antifactor VIII inhibitor. rFVIIa (75 μg/kg) was given before and after surgery...

...R.P. Kadota; E.J.W. Bowie; H.C. Emslander; D.N. Fass; D.M. Ilstrup A modified capillary thrombometer was constructed to study the rate of thrombus formation using heparinized whole blood (2 U/ml) obtained from normal adults (n = 22) and children (n = 20) and patients with hemophilia A (n = 10...

...-dependent glycoprotein, is not normally present in the blood. Upon tissue injury, however, coagulation is initiated by the activation of factors IX and X. The relationship of these events to the possibility that hemophilia A and B are tissue factor-dependent diseases is discussed. Tissue factor Factor...

.... The method is simple, rapid, painless and has no known adverse effects. Hemophilia Hematomas Hematoma of the psoas muscle Sonography 4 11 1975 26 01 1976 16 4 2009 © 1976 S. Karger AG, Basel 1976 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

...Louis M. Aledort //8R Hemophilia care is delivered differently in many parts of the world. Some areas of the world cannot diagnose hemophilia, other recognize the disease but do not have treatment, while others provide comprehensive care and have a plethora of services, as well as unlimited...

...T. Wenzel; G. Pindur; S. Mörsdorf; J. Giacchi Quality of live, defined by different models, has become a major focus of research in chronic disorders. Patients with hemophilia have been found to suffer seriously from the impact of HIV infection. To compare the impact of HIV infection on HIV...

...S. Arkin; H.A. Cooper; J.J. Hutter; S. Miller; M.L. Schmidt; N.L. Seibel; A. Shapiro; I. Warrier Activated recombinant human coagulation factor VII (rFVIIa) is a promising new therapeutic agent for patients with hemophilia A or B with inhibitors who experience serious bleeding episodes or who need...